Suplatast (Tosilate)
CAT:
804-HY-17002-03
Size:
500 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No

Suplatast (Tosilate)
- CAS Number: 94055-76-2
- UNSPSC Description: Suplatast Tosilate (IPD 1151T) is an orally active Th2 cytokine inhibitor which can inhibit both IL-4 and IL-5 production from Th2 cells and suppress IgE synthesis. Suplatast Tosilate is an anti-allergic agent. Suplatast Tosilate has antiasthmatic, anti-inflammatory and antifibrotic activity[1][2][3][4].
- Target Antigen: Interleukin Related
- Type: Reference compound
- Related Pathways: Immunology/Inflammation
- Applications: COVID-19-immunoregulation
- Field of Research: Inflammation/Immunology
- Assay Protocol: https://www.medchemexpress.com/Suplatast-Tosilate.html
- Solubility: DMSO : ≥ 33 mg/mL|H2O : ≥ 100 mg/mL
- Smiles: C[S+](C)CCC(NC1=CC=C(C=C1)OCC(COCC)O)=O.CC2=CC=C(C=C2)S(=O)([O-])=O
- Molecular Weight: 499.64
- References & Citations: [1]Furonaka M, Hattori N, Tanimoto T, Senoo T, Ishikawa N, Fujitaka K, Haruta Y, Yokoyama A, Kohno N.
 Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice.
 J Pharmacol Exp Ther. 2009 Jan;328(1):55-61.|[2]Yanagihara Y, et, al. Suppression of IgE production by IPD-1151T (suplatast tosilate), a new dimethylsulfonium agent: (2). Regulation of human IgE response. Jpn J Pharmacol. 1993 Jan;61(1):31-9.|[3]Zhao GD, et, al. Effect of suplatast tosilate (IPD-1151T) on a mouse model of asthma: inhibition of eosinophilic inflammation and bronchial hyperresponsiveness. Int Arch Allergy Immunol. 2000 Feb;121(2):116-22.|[4]Kurokawa M, et, al. Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo. Mediators Inflamm. 2001 Dec;10(6):333-7.
- Shipping Conditions: Room Temperature
- Clinical Information: Launched